Skip to content

Study · In vitro (cells) · 2014

9 results

LL-37 attenuates inflammatory impairment via mTOR signaling-dependent mitochondrial protection.

Sun W, Zheng Y, Lu Z, Wang H, Feng Z, Wang J, Xiao S, Liu F, Liu J

The international journal of biochemistry & cell biology28 Jun 2014Cited by 7 (Europe PMC)

PMID24984264 (opens in a new tab)DOI10.1016/j.biocel.2014.06.015 (opens in a new tab)PepBankPUB-24984264
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In HaCaT cells, LL‑37 reduced LPS-induced IL-6 mRNA levels and protein secretion.

    In plain wordsIn cells, LL‑37 reduced the inflammatory signal IL-6 that bacterial LPS had triggered.

    Peptide
    LL-37
    Outcome
    DecreaseLPS-induced IL-6 expression and secretion
    Study

    humann: not reported in source

    HaCaT cells
    Outcome group
    Inflammation markers · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    LL-37 was demonstrated to dramatically reduce the mRNA levels and protein secretion of inflammatory cytokines including IL-6, IL-8, IL-1α and tumor necrosis factor-α (TNF-α), which are induced by lipopolysaccharides (LPS).
    1 context sentence
    Summary · context
    Therefore, our aim was to investigate the immunomodulatory effect of LL-37 in HaCaT cells and to delineate the underlying mechanisms related to mitochondrial function.
  2. 02LabIn vitro (cells)Mechanism

    In HaCaT cells, LL‑37 reduced LPS-induced IL-8 mRNA levels and protein secretion.

    In plain wordsIn cells, LL‑37 reduced the inflammatory signal IL-8 that bacterial LPS had triggered.

    Peptide
    LL-37
    Outcome
    DecreaseLPS-induced IL-8 expression and secretion
    Study

    humann: not reported in source

    HaCaT cells
    Outcome group
    Inflammation markers · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    LL-37 was demonstrated to dramatically reduce the mRNA levels and protein secretion of inflammatory cytokines including IL-6, IL-8, IL-1α and tumor necrosis factor-α (TNF-α), which are induced by lipopolysaccharides (LPS).
    1 context sentence
    Summary · context
    Therefore, our aim was to investigate the immunomodulatory effect of LL-37 in HaCaT cells and to delineate the underlying mechanisms related to mitochondrial function.
  3. 03LabIn vitro (cells)Mechanism

    In HaCaT cells, LL‑37 reduced LPS-induced IL-1α mRNA levels and protein secretion.

    In plain wordsIn cells, LL‑37 reduced the inflammatory signal IL-1α that bacterial LPS had triggered.

    Peptide
    LL-37
    Outcome
    DecreaseLPS-induced IL-1α expression and secretion
    Study

    humann: not reported in source

    HaCaT cells
    Outcome group
    Inflammation markers · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    LL-37 was demonstrated to dramatically reduce the mRNA levels and protein secretion of inflammatory cytokines including IL-6, IL-8, IL-1α and tumor necrosis factor-α (TNF-α), which are induced by lipopolysaccharides (LPS).
    1 context sentence
    Summary · context
    Therefore, our aim was to investigate the immunomodulatory effect of LL-37 in HaCaT cells and to delineate the underlying mechanisms related to mitochondrial function.
  4. 04LabIn vitro (cells)Mechanism

    In HaCaT cells, LL‑37 reduced LPS-induced TNF-α mRNA levels and protein secretion.

    In plain wordsIn cells, LL‑37 reduced the inflammatory signal TNF-α that bacterial LPS had triggered.

    Peptide
    LL-37
    Outcome
    DecreaseLPS-induced TNF-α expression and secretion
    Study

    humann: not reported in source

    HaCaT cells
    Outcome group
    Inflammation markers · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    LL-37 was demonstrated to dramatically reduce the mRNA levels and protein secretion of inflammatory cytokines including IL-6, IL-8, IL-1α and tumor necrosis factor-α (TNF-α), which are induced by lipopolysaccharides (LPS).
    1 context sentence
    Summary · context
    Therefore, our aim was to investigate the immunomodulatory effect of LL-37 in HaCaT cells and to delineate the underlying mechanisms related to mitochondrial function.
  5. 05LabIn vitro (cells)Mechanism

    In HaCaT cells, the anti-inflammatory effects of LL‑37 depended on increased mitochondrial biogenesis and maintained mitochondrial homeostasis.

    In plain wordsIn cells, LL‑37 reduced inflammation by building more mitochondria and keeping them working.

    Peptide
    LL-37
    Outcome
    IncreaseMitochondrial biogenesis and homeostasis
    Study

    humann: not reported in source

    HaCaT cells
    Outcome group
    Mitochondrial function · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The anti-inflammatory effects of LL-37 are dependent upon its ability to increase mitochondrial biogenesis and to maintain mitochondrial homeostasis.
    1 context sentence
    Summary · context
    Therefore, our aim was to investigate the immunomodulatory effect of LL-37 in HaCaT cells and to delineate the underlying mechanisms related to mitochondrial function.
  6. 06LabIn vitro (cells)Mechanism

    In HaCaT cells, LL‑37 enhanced LPS-induced phosphorylation of ERK1/2.

    In plain wordsIn cells, LL‑37 increased the activation of the signalling protein ERK1/2 that LPS had triggered.

    Peptide
    LL-37
    Outcome
    IncreaseERK1/2 phosphorylation under LPS
    Study

    humann: not reported in source

    HaCaT cells
    Outcome group
    Receptor activity and mechanism · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, we observed that LL-37 enhances the LPS-induced phosphorylation of extracellular signal-regulated kinase (ERK1/2) and mammalian target of rapamycin (mTOR).
    1 context sentence
    Summary · context
    Therefore, our aim was to investigate the immunomodulatory effect of LL-37 in HaCaT cells and to delineate the underlying mechanisms related to mitochondrial function.
  7. 07LabIn vitro (cells)Mechanism

    In HaCaT cells, LL‑37 enhanced LPS-induced phosphorylation of mTOR.

    In plain wordsIn cells, LL‑37 increased the activation of the signalling protein mTOR that LPS had triggered.

    Peptide
    LL-37
    Outcome
    IncreasemTOR phosphorylation under LPS
    Study

    humann: not reported in source

    HaCaT cells
    Outcome group
    Receptor activity and mechanism · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, we observed that LL-37 enhances the LPS-induced phosphorylation of extracellular signal-regulated kinase (ERK1/2) and mammalian target of rapamycin (mTOR).
    1 context sentence
    Summary · context
    Therefore, our aim was to investigate the immunomodulatory effect of LL-37 in HaCaT cells and to delineate the underlying mechanisms related to mitochondrial function.
  8. 08LabIn vitro (cells)Mechanism

    In HaCaT cells, the mTOR inhibitor rapamycin neutralized the protective effects of LL‑37 on mitochondria.

    In plain wordsIn cells, the mTOR blocker rapamycin cancelled the protective effect of LL‑37 on mitochondria.

    Peptide
    LL-37
    Outcome
    No significant changeLL-37 mitochondrial protection with rapamycin
    Study

    humann: not reported in source

    HaCaT cells
    Outcome group
    Mitochondrial function · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The mTOR inhibitor rapamycin can neutralize the protective effects of LL-37 on mitochondria.
    1 context sentence
    Summary · context
    Therefore, our aim was to investigate the immunomodulatory effect of LL-37 in HaCaT cells and to delineate the underlying mechanisms related to mitochondrial function.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 09HumanEndogenous levelObservational studyOther

    In tissue microarrays of chronic skin inflammation, LL‑37 staining was strong in the cytoplasm of inflammatory cells.

    In plain wordsIn tissue samples from chronic skin inflammation, the body's own LL‑37 stained strongly inside inflammatory cells.

    Peptide
    LL-37
    Outcome
    IncreaseLL-37 staining in chronic dermatic inflammation
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Skin and wound

    Source sentences

    Summary
    Immunohistochemistry results from tissue microarrays showed strong cytoplasmic LL-37 staining in inflammatory cells in chronic dermatic inflammation.

    This result measures the body's own LL-37. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:57 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.